Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial

Citation
Bajaj HS, Raz I, Mosenzon O, et al. Diabetes Obes Metab 2020; epub ahead of press.